Searchable abstracts of presentations at key conferences in endocrinology

ea0075m08 | Metabolic Bone | EYES2021

Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials

Hasenmajer Valeria , Puliani Giulia , Sada Valentina , Tarantino Chiara , Lenzi Andrea , Isidori Andrea

Introduction: Hypoparathyroidism is the only endocrine deficiency for which replacement therapy with the missing hormone is not part of the clinical practice. High quality evidence on the use of PTH 1-34 or PTH 1-84 in hypoparathyroidism is missing.Objective: We aim to evaluate the efficacy and safety of PTH 1-34 and PTH 1-84, and to compare the two treatments when possible.Methods: We searched databases up to March 2021 for random...

ea0090p114 | Endocrine-related Cancer | ECE2023

Hyperandrogenism in menopause: whose fault?

Bonaventura Ilaria , Tomaselli Alessandra , Minnetti Marianna , De Alcubierre Dario , Tarantino Chiara , Cozzolino Alessia , Pofi Riccardo , Gianfrilli Daniele , Isidori Andrea , Pozza Carlotta

Background: Hyperandrogenism in postmenopausal women is extremely rare and requires exclusion of malignancy.Case reports: 1. A 65-year-old woman was referred to our Department of Endocrinology for appearance of hirsutism and alopecia for about 2 years. Abdomen-pelvis CT scan showed a 2-cm lesion (45 HU) at the left adrenal gland, confirmed by MRI scan, without loss of signal intensity in opposed-phase sequences. In addition, in the right ovary, a 3-cm le...

ea0099ep293 | Reproductive and Developmental Endocrinology | ECE2024

Impact of drospirenone-only-pill on sexual function: experience of our‘pcos and female endocrinology outpatient clinic’

Tomaselli Alessandra , Minnetti Marianna , Rosato Elena , Tarantino Chiara , De Alcubierre Dario , Ferrari Davide , Rizzo Flavio , Sciarra Francesca , Pofi Riccardo , Isidori Andrea , Pozza Carlotta

Introduction and Objectives of the Study: Combined oral contraceptives (COCs) are frequently prescribed for fertility control, however sexual dysfunction has been reported as a common side effect. In 2020, a novel progestin-only pill containing Drospirenone (DRSP) was approved as an oral contraceptive. To date, here is a notable dearth of data on the impact of DRSP on sexual function and impact on hormones, particularly regarding steroids. This study aims to investigate the po...